PMID- 32921680
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20221207
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 84
IP  - 10
DP  - 2020 Sep 25
TI  - Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary 
      Hypertension in Type 2 Diabetes Patients　- A Randomized Controlled Trial.
PG  - 1807-1817
LID - 10.1253/circj.CJ-20-0341 [doi]
AB  - BACKGROUND: This prospective randomized multicenter open-label trial evaluated 
      whether sodium-glucose cotransporter-2 inhibitor (SGLT2-i) improves left 
      ventricular (LV) pump function and suppresses elevation of LV filling pressure 
      (LVFP) and right ventricular systolic pressure (RVSP) during exercise in type 2 
      diabetes mellitus (T2DM) patients.Methods and Results:Based on HbA1c and LV 
      ejection fraction, 78 patients with poorly controlled T2DM were randomly assigned 
      to D-group (dapagliflozin 5 mg/day add-on) or C-group (conventional therapy 
      add-on). Physical examination, home and office blood pressure examination, blood 
      tests, and echocardiography at rest and during ergometer exercise were performed 
      at baseline and at 1.5 and 6 months after treatment. The primary endpoint was 
      defined as the change in RVSP (mmHg) between baseline and 6-month follow up. The 
      secondary endpoints were changes in LVFP (ratio), stroke volume index (SVi; 
      mL/m(2)), and cardiac index (CI; L/min/m(2)). Both RVSP and LVFP during exercise 
      significantly decreased from baseline to 6 months after starting treatment in the 
      D-group (P<0.001). No changes to either parameter was observed in the C-group. 
      The SVi and CI did not improve in either group. Both home and office blood 
      pressure significantly decreased in the D-group. Decreases in HbA1c were somewhat 
      greater in the C-group. CONCLUSIONS: Dapagliflozin significantly improved RVSP 
      and LVFP during exercise in patients with T2DM and cardiovascular risk, which may 
      contribute to favorable effects on heart failure.
FAU - Kayano, Hiroyuki
AU  - Kayano H
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Koba, Shinji
AU  - Koba S
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Hirano, Tsutomu
AU  - Hirano T
AD  - Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Showa 
      University School of Medicine.
FAU - Matsui, Taiju
AU  - Matsui T
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Fukuoka, Hiroto
AU  - Fukuoka H
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Tsuijita, Hiroaki
AU  - Tsuijita H
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Tsukamoto, Shigeto
AU  - Tsukamoto S
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Hayashi, Toshiyuki
AU  - Hayashi T
AD  - Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Showa 
      University School of Medicine.
FAU - Toshida, Tsutomu
AU  - Toshida T
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Watanabe, Norikazu
AU  - Watanabe N
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Hamazaki, Yuji
AU  - Hamazaki Y
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Geshi, Eiichi
AU  - Geshi E
AD  - Department of Internal Medicine, Showa University School of Nursing and 
      Rehabilitation Sciences.
FAU - Murakami, Mikitaka
AU  - Murakami M
AD  - Murakami Cardiology and Medical Clinic.
FAU - Aihara, Kazuo
AU  - Aihara K
AD  - Aihara Medical Clinic.
FAU - Kaneko, Koujin
AU  - Kaneko K
AD  - Kaneko Clinic.
FAU - Yamada, Hirokazu
AU  - Yamada H
AD  - Soiken Inc.
AD  - EviPRO Co., Ltd.
FAU - Kobayashi, Youichi
AU  - Kobayashi Y
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
FAU - Shinke, Toshiro
AU  - Shinke T
AD  - Department of Medicine, Division of Cardiology, Showa University School of 
      Medicine.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200912
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Aged
MH  - Benzhydryl Compounds/*administration & dosage
MH  - Blood Pressure/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*complications/epidemiology
MH  - *Exercise
MH  - Female
MH  - Follow-Up Studies
MH  - Glucosides/*administration & dosage
MH  - Glycated Hemoglobin/analysis
MH  - Heart Failure/prevention & control
MH  - Humans
MH  - Hypertension, Pulmonary/blood/*complications/*drug therapy/epidemiology
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sodium-Glucose Transporter 2 Inhibitors/*administration & dosage
MH  - Stroke Volume/*drug effects
MH  - Treatment Outcome
MH  - Ventricular Function, Left/*drug effects
OTO - NOTNLM
OT  - Cardiac function
OT  - Dapagliflozin
OT  - Echocardiography
OT  - Exercise
EDAT- 2020/09/15 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/09/14 05:47
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/09/14 05:47 [entrez]
AID - 10.1253/circj.CJ-20-0341 [doi]
PST - ppublish
SO  - Circ J. 2020 Sep 25;84(10):1807-1817. doi: 10.1253/circj.CJ-20-0341. Epub 2020 
      Sep 12.